HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

HCW Biologics (HCWB) announced that its scientists and academic collaborators at Queen’s University at Kingston, Ontario discovered that HCW11-040, a second-generation, pembrolizumab-based fusion immunotherapeutic, prevents bronchopulmonary dysplasia during IND-Enabling studies. “At the outset on the road to our discovery of the potential for HCW11-040 to treat BPD, our hypothesis was that immune checkpoint inhibitors have the potential to treat diseases beyond cancer, since they have also recently been identified as effective senomorphic drugs for senescent cell removal to treat age-related or stressor-induced related diseases,” said Hing Wong, founder and CEO.